Cordycepin
Alternative Names: NSC 63984Latest Information Update: 24 Sep 2021
At a glance
- Originator OXiGENE
- Developer National Cancer Institute (USA); Tufts-New England Medical Center
- Class Amines; Antifungals; Antineoplastics; Nucleosides; Purines; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Candidiasis; Chronic myeloid leukaemia; Parasitic infections; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 11 Jun 2002 Discontinued - Phase-I for Acute lymphoblastic leukaemia in USA (unspecified route)
- 11 Jun 2002 Discontinued - Phase-I for Chronic myeloid leukaemia in USA (unspecified route)
- 11 Jun 2002 Discontinued - Preclinical for Candidiasis in USA (unspecified route)